{
    "clinical_study": {
        "@rank": "31639", 
        "arm_group": [
            {
                "arm_group_label": "CRD007 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "CRD007, 10 mg tablet, single dose"
            }, 
            {
                "arm_group_label": "CRD007  25 mg", 
                "arm_group_type": "Experimental", 
                "description": "CRD007, 25 mg tablet, single dose"
            }, 
            {
                "arm_group_label": "CRD007 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "CRD007, 40 mg tablet, single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the plasma levels of CRD007 in patients with\n      abdominal aortic aneurysms after the administration of single doses of tablets containing\n      10, 25 and 40 mg CRD007."
        }, 
        "brief_title": "Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Abdominal Aortic Aneurisms", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Aortic Aneurysm", 
                "Aortic Aneurysm, Abdominal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infra-renal abdominal aortic aneurysm\n\n        Exclusion Criteria:\n\n          -  Significant concurrent disease or medical conditions that are deemed to interfere\n             with the pharmacokinetics or the safety of CRD007 conduct of the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723618", 
            "org_study_id": "Cardoz-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "CRD007 10 mg", 
                "CRD007  25 mg", 
                "CRD007 40 mg"
            ], 
            "intervention_name": "CRD007", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Viborg", 
                    "country": "Denmark", 
                    "zip": "8800"
                }, 
                "name": "Department of Vascular Surgery Viborg Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)", 
        "overall_official": {
            "affiliation": "Department of Vascular Surgery  Viborg Hospital Heiberg All\u00e9 4 DK-8800 Viborg Denmark", 
            "last_name": "Nikolaj F Groendal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Health and Medicines Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as Cmax will be measured", 
                "measure": "Pharmacokinetics - maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and until 12 hours post-dose"
            }, 
            {
                "description": "Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as tmax will be measured.", 
                "measure": "Pharmacokinetics - time to maximum plasma concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose til 12 hours post-dose"
            }, 
            {
                "description": "Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as AUC will be measured.", 
                "measure": "Pharmacokinetics - Area under the plasma concentration curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose until 12 hours post-dose"
            }, 
            {
                "description": "Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as t1/2 will be measured", 
                "measure": "Pharmacokinetics - elimination half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose until 12 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723618"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of dose linearity in the dose range 10 - 40 mg", 
                "measure": "Dose linearity", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and until 12 hours post-dose"
            }, 
            {
                "description": "To estimate the accumulation of CRD007 in the dose range 10 - 40 mg", 
                "measure": "Potential for accumulation", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose untill 12 hours post-dose"
            }
        ], 
        "source": "Cardoz AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardoz AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}